Bioventus (BVS) Stock Analysis: AI Score & Alternative Data
BVS alt-data: business outlook climbing, web traffic lagging
Is Bioventus a buy right now? The alternative data leans yes. This BVS stock analysis is built on the 25+ alternative data signals AltIndex tracks on Bioventus every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 60/100: a Buy. The stock trades at $14.07 with a $982M market cap.
What’s driving the buy signal over the past 90 days: 70% of employees are positive on the business outlook. The watch-item: web traffic down 23.0% to 14K monthly visits.
BVS’s broader alt-data profile also covers job postings (67 open roles), headcount (1K employees, according to LinkedIn), quarterly revenue ($150M), and YouTube subscribers (27K). Every signal links to its own page with full history, the BVS technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on BVS is just below.
Bioventus AI Stock Analysis
Bioventus Inc. focuses on the development and commercialization of clinically therapeutically used orthobiologic solutions. The company's products are primarily focused on the musculoskeletal sector, providing treatments to help patients with orthopedic conditions heal faster and recover from surgeries more effectively.
Analysis generated August 5, 2026.
Recent Bioventus Stock Alerts
|
Bioventus | August 6 Price is down by -7% in the last 24h. |
|
Bioventus | August 5 Price is up by 12.4% in the last 24h. |
|
Bioventus | July 28 Price is up by 6% in the last 24h. |
|
Bioventus | July 13 Employee Rating is up by 2.9% over the last month. |
Bioventus Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 14K | 23.0% | |
| Job Posts | 67 | 3.1% | |
| LinkedIn Employees | 1K | 2.4% | |
| Employee Recommend | 74 | 2.8% | |
| Business Outlook | 70 | 4.5% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 1 | 83.3% | |
| Stocktwits Mentions | 0 | 100.0% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 481 | 7.1% | |
| 4chan Mentions | 0 | N/A | |
| X Followers | 2K | 0% | |
| Instagram Followers | 860 | 4.9% | |
| Youtube Subscribers | 27K | 0% | |
| Facebook Followers | 690 | 0% | |
| Facebook Engagement | 0 | 100.0% |
About Bioventus (BVS)
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body’s natural healing process in the United States and internationally.
| Price | $14.07 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $982M |
| Year Range | $7 – $15 |
| Dividend Yield | 0% |
| PE Ratio | 17.5 |
| Analyst Rating | 38% buy |
| Industry | Medical Devices |
Latest Bioventus News
View more → |
Bioventus Q2 Earnings Call HighlightsAugust 5 - Biztoc.com |
Bioventus Reports Second Quarter Financial ResultsAugust 5 - GlobeNewswire |
|
 |
Did Bioventus Inc. Insiders Breach their Fiduciary Duties to Shareholders?July 3 - PRNewswire |
Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare ConferenceJune 2 - GlobeNewswire |
|
Bioventus Q1 Earnings Call HighlightsMay 6 - MarketBeat |
See Bioventus’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for BVS, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEBioventus Earnings & Financial Performance
View all earnings →Bioventus Insider Trading Activity
View all →| McMurry-Heath Michelle filed to sell 44,997 shares at $0.0. Mar 11 '26 |
| NOHRA GUY P filed to sell 116,610 shares at $0.0. Dec 4 '25 |
| McMurry-Heath Michelle filed to sell 56,997 shares at $0.0. Nov 7 '25 |
| CHURCH KATRINA J filed to sell 55,557 shares at $0.0. Apr 11 '25 |
| D'Adamio Anthony filed to sell 131,416 shares at $0.0. Apr 11 '25 |
Bioventus Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Bioventus
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
InmodeINMD |
$14.91 0.5% | $860M | 41 |
 |
Avanos MedicalAVNS |
$24.99 0.0% | $1B | 45 |
 |
PROCEPT BioRoboticsPRCT |
$22.76 6.5% | $1B | 48 |
 |
ArtivionAORT |
$25.57 0.2% | $1B | 54 |
 |
Integra LifesciencesIART |
$16.72 1.7% | $1B | 41 |
Explore Bioventus Data
Frequently Asked Questions: Bioventus (BVS)
Bioventus has an AltIndex AI Score of 60/100 (Buy). The score reflects positive alternative data signals. All investments carry risk.
60/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Bioventus (BVS) stock is $14.07 with a market cap of $982M.
As of today, Bioventus’s PE (Price to Earnings) ratio is 17.5.
View the latest Bioventus insider transactions to see recent buying and selling activity by company executives and directors.
Check the Bioventus congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The BVS stock price chart above shows Bioventus’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Bioventus technical analysis for RSI, moving averages, and more.
See the stocks similar to Bioventus section on this page for companies in the same industry ranked by market cap and AI Score.
